Before initiating treatment with EGFR-TKIs, a rigorous baseline risk assessment must be performed on all patients, and baseline cardiovascular risk factors, including obesity, diabetes, hypertension, smoking, etc., must be carefully considered. The gene discussed is EGFR; the disease is hypertensive disorder.